Search
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that … Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.
Acrivastine
go.drugbank.com/drugs/DB09488ApprovedAs an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension … Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalImipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Proparacaine
go.drugbank.com/drugs/DB00807ApprovedVet approvedIt is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigationalAlthough administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. … [A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent.
Palonosetron
go.drugbank.com/drugs/DB00377ApprovedInvestigationalAs of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalIt is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). … When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time.
Tyloxapol
go.drugbank.com/drugs/DB06439ApprovedInvestigationalTyloxapol is a non-ionic detergent often used as a surfactant.
Fulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalWhile it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative